Di Lauro L, Fattoruso Au moment ou, Giacinti L, et al. Second-line radiation treatment with FOLFIRI during the people having metastatic gastric malignant tumors (MGC) maybe not in the past given fluoropyrimidines. J Clin Oncol. 2009. s (suppl; abstr 4549).
Burtness B, Gibson Meters, Egleston B, ainsi que al. Phase II trial regarding docetaxel-irinotecan consolidation for the cutting-edge esophageal malignant tumors. Ann Oncol. 2009 Jul. 20(7):1242-8. [QxMD MEDLINE Connect].
A period II trial researching capecitabine and irinotecan as second-line procedures inside patients that have oesophago-gastric cancer tumors who possess developed with the, otherwise within this ninety days out-of rare metal-founded radiation treatment
Catenacci DVT, Kang YK, Playground H, et al. Margetuximab together with pembrolizumab inside the people with in the past addressed, HER2-self-confident gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-case, phase 1b-dos demonstration. Lancet Oncol. 2020 Aug. 21 (8):1066-1076. [QxMD MEDLINE Hook up]. [Complete Text].
Doebele Remote-controlled, Drilon A, Paz-Ares L, Siena S, et al. Entrectinib inside the clients having complex or metastatic NTRK collection-self-confident strong tumours: incorporated study of three-phase step 1-dos samples. Lancet Oncol. 2020 Feb. 21 (2):271-282. [QxMD MEDLINE Hook up]. [Full Text].
Drilon A great, Laetsch TW, Kummar S, DuBois SG, mais aussi al. Effectiveness regarding Larotrectinib during the TRK Collection-Self-confident Malignant tumors inside Adults and children. N Engl J Med. 2018 Feb twenty two. 378 (8):731-739. [QxMD MEDLINE Connect]. [Full Text message].
Ce DT, Durham JN, Smith KN, ainsi que al. Mismatch fix deficit forecasts reaction regarding solid tumors to PD-step one blockade. Science http://www.datingmentor.org/escort/overland-park/. 2017 Jul twenty eight. 357 (6349):409-413. [QxMD MEDLINE Hook].
Le DT, Uram JN, Wang H, ainsi que al. PD-1 Blockade in the Cancers that have Mismatch-Repair Lack. N Engl J Med. 2015 Jun 25. 372 (26):2509-20. [QxMD MEDLINE Hook up].
You. Sahin, O
Tabernero J, Yoshino T, Cohn AL, Obermanucirumab in the place of placebo in conjunction with 2nd-line FOLFIRI inside the people which have metastatic colorectal carcinoma you to definitely progressed during the otherwise just after earliest-line procedures which have bevacizumab, oxaliplatin, and you may a good fluoropyrimidine (RAISE): an effective randomised, double-blind, multicentre, stage step three study. Lancet Oncol. 2015 May. sixteen (5):499-508. [QxMD MEDLINE Hook up]. [Full Text].
Mitani S, Kadowaki S, Komori An excellent, Kondoh C, Oze We, Kato K, et al. A period II Study of Altered FOLFOX6 to have State-of-the-art Gastric Cancer Refractory in order to Basic Therapy. Adv Ther. 2020 Jun. 37 (6):2853-2864. [QxMD MEDLINE Connect]. [Complete Text].
Shitara K, Doi T, Dvorkin Meters, Mansoor W, Arkenau HT, Prokharau A great, et al. Trifluridine/tipiracil rather than placebo inside clients which have greatly pretreated metastatic gastric disease (TAGS): a good randomised, double-blind, placebo-managed, stage step three demonstration. Lancet Oncol. 2018 Late. 19 (11):1437-1448. [QxMD MEDLINE Hook].
Kawazoe An excellent, Ando T, Hosaka H, Fujita J, Koeda K, Nishikawa K, et al. Safeguards and interest off trifluridine/tipiracil and you will ramucirumab when you look at the before addressed complex gastric malignant tumors: an unbarred-identity, single-sleeve, stage dos demonstration. Lancet Gastroenterol Hepatol. 2021 Mar. 6 (3):209-217. [QxMD MEDLINE Hook]. [Full Text message].
Chen LT, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, ainsi que al. A stage 3 study of nivolumab during the prior to now managed state-of-the-art gastric otherwise gastroesophageal junction cancer tumors (ATTRACTION-2): 2-12 months improve analysis. Gastric Disease. 2020 Will get. 23 (3):510-519. [QxMD MEDLINE Hook up]. [Full Text message].
Fukuoka S, Hara H, Takahashi Letter, Kojima T, Kawazoe An excellent, Asayama Meters, ainsi que al. Regorafenib And additionally Nivolumab in the People That have Cutting-edge Gastric or Colorectal Disease: An unbarred-Name, Dose-Escalation, and Amount-Extension Stage Ib Demonstration (REGONIVO, EPOC1603). J Clin Oncol. 2020 Jun 20. 38 (18):2053-2061. [QxMD MEDLINE Connect]. [Complete Text message].
Tureci, Grams. Manikhas, et. al. FAST: an effective randomised stage II study of zolbetuximab (IMAB362) also EOX in the place of EOX alone for very first-line treatments for advanced CLDN18.2-confident gatric and gastro-oesophageal adenocarcinoma. Annals from Oncology. 2021 May. Vol -619. [Full Text].
Nivolumab lengthened situation 100 % free success into the clients having resected (R0) stage II or III esophageal otherwise gastroesophageal junction cancers which acquired neoadjuvant chemoradiotherapy together with residual pathological condition.
Docetaxel 70-85 mg/meters 2 IV for the date step one also cisplatin 70-75 milligrams/yards dos IV with the date 1; every 21 d [45, 46, 47] otherwise
Javle MM, Yang G, Nwogu Le, mais aussi al. Capecitabine, oxaliplatin and radiation therapy: a phase IB neoadjuvant research for esophageal cancer tumors which have gene term study. Cancer Dedicate. 2009 Feb. 27(2):193-2 hundred. [QxMD MEDLINE Hook].
Enzinger Pc, Burtness BA, Niedzwiecki D, Ye X, ainsi que al. CALGB 80403 (Alliance)/E1206: A Randomized Stage II Examination of About three Radiation treatment Regimens Together with Cetuximab in the Metastatic Esophageal and Gastroesophageal Aug 10. 34 (23):2736-42. [QxMD MEDLINE Connect]. [Complete Text].
Albertsson Meters, Johansson B, Friesland S, ainsi que al. Stage II knowledge towards docetaxel by yourself all of the third times, or weekly in combination with gemcitabine in people with primary in your town state-of-the-art, metastatic, otherwise perennial esophageal cancer tumors. Med Oncol. 2007. 24(4):407-12. [QxMD MEDLINE Hook].
Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua Roentgen, Goswami C, et al. Ramucirumab monotherapy for previously handled cutting-edge gastric otherwise gastro-oesophageal junction adenocarcinoma (REGARD): a global, randomised, multicentre, placebo-regulated, phase 3 trial. Lancet. 2014 Jan cuatro. 383(9911):31-9. [QxMD MEDLINE Hook up].